BGPT: list the indications approved for dupilimab and the dates

Explore by Goal

Quick Explanation Copied

Assuming U.S. FDA approvals, dupilumab (Dupixent) has six disease indications as of August 25, 2026: atopic dermatitis (2017), asthma (2018), chronic rhinosinusitis with nasal polyps (2019), eosinophilic esophagitis (2022), prurigo nodularis (2022), and COPD with an eosinophilic phenotype (2025). The dates below are the original FDA approval dates, not later age-range or labeling expansions.

Long Explanation

U.S. FDA indication timeline

Indication	Original approval
Moderate-to-severe atopic dermatitis	March 28, 2017
Moderate-to-severe eosinophilic asthma	October 19, 2018
Chronic rhinosinusitis with nasal polyps	June 26, 2019
Eosinophilic esophagitis	May 20, 2022
Prurigo nodularis	September 27, 2022
COPD with an eosinophilic phenotype	May 2025

The first five dates are documented in FDA approval announcements or FDA approval records: atopic dermatitis ; asthma ; nasal polyps ; eosinophilic esophagitis ; and prurigo nodularis . The COPD indication was approved by FDA in 2025 for adults with inadequately controlled COPD and an eosinophilic phenotype; the FDA communication and current label support the year, but the exact approval-day date should be checked against the dated FDA approval letter or updated Drugs@FDA record before citing a day-level date.

Scope: This is the U.S. FDA disease-indication timeline. European Union, United Kingdom, and other jurisdictions can have different dates, wording, age limits, and regulatory status. Later pediatric approvals and label expansions are intentionally not counted as new disease indications. Confidence is high for the first five dates and the six-indication list; confidence is moderate for the COPD month/day because the accessible regulatory label establishes the indication but not a complete historical chronology.